4.8 Article

Deletion of steroid receptor coactivator-3 gene ameliorates hepatic steatosis

期刊

JOURNAL OF HEPATOLOGY
卷 55, 期 2, 页码 445-452

出版社

ELSEVIER
DOI: 10.1016/j.jhep.2010.11.022

关键词

-

资金

  1. 973 Project [2006CB503904]
  2. 863 Project [2006 AA 02A409]
  3. National Natural Science Foundation of China [30725037, 30971077, 30971385]
  4. Shanghai Committee for Science and Technology [07JC14042]

向作者/读者索取更多资源

Background & aims: Excess dietary fat can cause hepatic steatosis, which can progress into severe liver disorders including steatohepatitis and cirrhosis. Steroid receptor coactivator-3 (SRC-3), a member of the p160 coactivator family, is reported as a key regulator of adipogenesis and energy homeostasis. We sought to determine the influence of SRC-3 on hepatic steatosis and the mechanism beneath. Methods: The influence of siRNA-mediated SRC-3 silencing on hepatic lipid accumulation was assessed in HepG2 cells. The molecular mechanism of SRC-3 regulation of hepatic lipid metabolism was also studied. Moreover, the effect of SRC-3 ablation on hepatic steatosis was examined in SRC-3 deficient mice. Results: In this study, we report that SRC-3 ablation reduces palmitic acid-induced lipid accumulation in HepG2 cells. Moreover, deletion of SRC-3 ameliorates hepatic steatosis and inflammation response in mice fed a high fat diet (HFD). These metabolic improvements can presumably be explained by the reduction in chicken ovalbumin upstream promoter transcription factor II (COUP-TFII) expression and the subsequent elevation in peroxisome proliferator-activated receptor alpha (PPAR alpha) level. At the molecular level, SRC-3 interacts with retinoic receptor a (RAR alpha) to activate COUP-TFII expression under all-trans retinoic acid (ARTA) treatment. Conclusions: These findings indicate a crucial role for SRC-3 in regulating hepatic lipid metabolism and provide the possible novel inner mechanisms. (C) 2011 Published by Elsevier B.V. on behalf of the European Association for the Study of the Liver.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Gastroenterology & Hepatology

N6-Methyladenosine Reader Protein YT521-B Homology Domain-Containing 2 Suppresses Liver Steatosis by Regulation of mRNA Stability of Lipogenic Genes

Bing Zhou, Caizhi Liu, Lingyan Xu, Youwen Yuan, Jiejie Zhao, Wenjun Zhao, Yiyan Chen, Jin Qiu, Meiyao Meng, Ying Zheng, Dongmei Wang, Xin Gao, Xiaoying Li, Qihong Zhao, Xiaohui Wei, Duojiao Wu, Huijie Zhang, Cheng Hu, Xiaozhen Zhuo, Minghua Zheng, Hua Wang, Yan Lu, Xinran Ma

Summary: In this study, it was found that m(6)A enrichment and mRNA expression of lipogenic genes were increased in leptin-receptor-deficient mice. The m(6)A reader, Ythdc2, was down-regulated in obese mice and NAFLD patients, and its suppression in lean mice led to TG accumulation while overexpression in obese mice improved liver steatosis and insulin resistance. This suggests that Ythdc2 plays a crucial role in regulating hepatic lipogenesis and TG homeostasis, presenting a potential target for treating obesity-related NAFLD.

HEPATOLOGY (2021)

Review Endocrinology & Metabolism

Glucose-lowering pharmacotherapies in Chinese adults with type 2 diabetes and cardiovascular disease or chronic kidney disease. An expert consensus reported by the Chinese Diabetes Society and the Chinese Society of Endocrinology

Tianpei Hong, Qing Su, Xiaoying Li, Zhongyan Shan, Li Chen, Yongde Peng, Liming Chen, Li Yan, Yuqian Bao, Zhaohui Lyu, Lixin Shi, Weiqing Wang, Lixin Guo, Guang Ning, Yiming Mu, Dalong Zhu

Summary: It is important to assess and screen for cardiovascular risk factors, ASCVD and CKD in patients with T2DM. Metformin is recommended as a first-line therapy and additional medications like GLP-1RA or SGLT2 inhibitors may be considered for patients with established ASCVD, HF, or CKD. Comprehensive regimen including lifestyle intervention and management of multiple risk factors should be part of the treatment strategy for these patients.

DIABETES-METABOLISM RESEARCH AND REVIEWS (2021)

Article Genetics & Heredity

Circ_LARP4 regulates high glucose-induced cell proliferation, apoptosis, and fibrosis in mouse mesangial cells

Yakun Wang, Yinghui Qi, Tingting Ji, Bo Tang, Xiaoying Li, Pengxi Zheng, Shoujun Bai

Summary: In diabetic nephropathy, the expression level of circ_LARP4 is lower than in normal cells. Overexpression of circ_LARP4 can inhibit cell proliferation and fibrosis, but increase cell apoptosis, possibly through its sponge action on miR-424.
Review Endocrinology & Metabolism

Titratable fixed-ratio combination of basal insulin plus a glucagon-like peptide-1 receptor agonist: A novel, simplified alternative to premix insulin for type 2 diabetes

Fernando Gomez-Peralta, Ebaa Al-Ozairi, Edward B. Jude, Xiaoying Li, Julio Rosenstock

Summary: Despite numerous therapeutic options, many type 2 diabetes patients fail to achieve their HbA1c targets. This review examines the limitations of premix insulin injections and explores the potential benefits of fixed-ratio combinations (FRCs) of basal insulin and GLP-1 RAs as an alternative treatment option for intensification therapy. Results suggest that FRCs may offer improved HbA1c reductions, lower risk of hypoglycemia, and less weight gain compared to premix insulin in a simplified treatment regimen.

DIABETES OBESITY & METABOLISM (2021)

Article Immunology

Hepatic Gadd45β promotes hyperglycemia and glucose intolerance through DNA demethylation of PGC-1α

Ling Wu, Yang Jiao, Yao Li, Jingjing Jiang, Lin Zhao, Menghui Li, Bin Li, Zheng Yan, Xuejin Chen, Xiaoying Li, Yan Lu

Summary: This study identified a pathway dependent on Gadd45 beta that stimulates hepatic glucose production, leading to hyperglycemia, while liver-specific Gadd45 beta-knockout mice showed resistance to high-fat diet or steroid-induced hyperglycemia. This suggests that Gadd45 beta promotes DNA demethylation, resulting in gluconeogenesis and hyperglycemia.

JOURNAL OF EXPERIMENTAL MEDICINE (2021)

Article Gastroenterology & Hepatology

Hepatic Small Ubiquitin-Related Modifier (SUMO)-Specific Protease 2 Controls Systemic Metabolism Through SUMOylation-Dependent Regulation of Liver-Adipose Tissue Crosstalk

Yang Liu, Xin Dou, Wei-Yu Zhou, Meng Ding, Ling Liu, Ruo-Qi Du, Liang Guo, Shu-Wen Qian, Yan Tang, Qi-Qi Yang, Dong-Ning Pan, Xiao-Ying Li, Yan Lu, Jin-Ke Cheng, Qi-Qun Tang

Summary: The liver-specific knockout of SENP2 in mice showed resistance to high-fat diet-induced hepatic steatosis and obesity, upregulation of genes involved in fatty acid oxidation, and downregulation of genes in lipogenesis. Additionally, ablation of hepatic SENP2 activated thermogenesis in adipose tissues, promoting energy homeostasis. FGF21 was identified as a key factor in maintaining metabolic balance in SENP2 knockout mice.

HEPATOLOGY (2021)

Article Medicine, Research & Experimental

Identification of circulating sphingosine kinase-related metabolites for prediction of type 2 diabetes

Qi Chen, Wei Wang, Ming-Feng Xia, You-li Lu, Hua Bian, Chen Yu, Xiao-Ying Li, Mathew A. Vadas, Xin Gao, Huan-Dong Lin, Pu Xia

Summary: Circulating levels of dhS1P and dhS1P/dhSph ratio are strongly associated with increased risk of T2DM, and could serve as a useful biomarker for predicting incident T2DM in normoglycemic populations.

JOURNAL OF TRANSLATIONAL MEDICINE (2021)

Article Cell Biology

FOXO3a Protects against Kidney Injury in Type II Diabetic Nephropathy by Promoting Sirt6 Expression and Inhibiting Smad3 Acetylation

Xiaowei Wang, Tingting Ji, Xiaoying Li, Xiaolei Qu, Shoujun Bai

Summary: The study reveals that FOXO3a protects against injury in type II diabetic nephropathy by increasing Sirt6 expression, which inhibits Smad3 transcriptional activity. This highlights the potential therapeutic strategy of targeting the FOXO3a-mediated Sirt6/Smad3 signaling pathways in treating type II diabetic nephropathy.

OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2021)

Article Cell Biology

Exosomal hsa_circ_0125310 promotes cell proliferation and fibrosis in diabetic nephropathy via sponging miR-422a and targeting the IGF1R/p38 axis

Yingchun Zhu, Fangfang Zha, Bo Tang, Ting-Ting Ji, Xiao-Ying Li, Linhong Feng, Shou-Jun Bai

Summary: The study found that high glucose-induced circ_0125310 promotes the progression of diabetic nephropathy by regulating miR-422a and the IGF1R/p38 axis.

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2022)

Review Cell Biology

The Role and Mechanism of Oxidative Stress and Nuclear Receptors in the Development of NAFLD

Ting Hong, Yiyan Chen, Xiaoying Li, Yan Lu

Summary: The overproduction of ROS and oxidative stress play crucial roles in the pathogenesis of acute and chronic liver diseases. NAFLD is characterized as a redox-centered disease, and dysregulation of nuclear receptors (NRs) may be key in regulating this process. Targeting NRs could be a promising strategy for improving oxidation damage and treating NAFLD.

OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2021)

Article Multidisciplinary Sciences

Multiplexed nanomaterial-assisted laser desorption/ionization for pan-cancer diagnosis and classification

Hua Zhang, Lin Zhao, Jingjing Jiang, Jie Zheng, Li Yang, Yanyan Li, Jian Zhou, Tianshu Liu, Jianmin Xu, Wenhui Lou, Weige Yang, Lijie Tan, Weiren Liu, Yiyi Yu, Meiling Ji, Yaolin Xu, Yan Lu, Xiaomu Li, Zhen Liu, Rong Tian, Cheng Hu, Shumang Zhang, Qinsheng Hu, Yangdong Deng, Hao Ying, Sheng Zhong, Xingdong Zhang, Yunbing Wang, Hua Wang, Jingwei Bai, Xiaoying Li, Xiangfeng Duan

Summary: As cancer is increasingly seen as a metabolic disorder, serum metabolite profiling is proposed as a viable method for detecting cancer. In this study, a machine learning model using mass spectrometry-based liquid biopsy data is reported for pan-cancer screening and classification. The Multiplexed Nanomaterial-Assisted LDI for Cancer Identification (MNALCI) achieves high sensitivity and specificity for distinguishing cancers from healthy controls and accurately identifying the tissue of origin of tumors. This high throughput assay shows promising potential for non-invasive cancer diagnosis.

NATURE COMMUNICATIONS (2022)

Article Biochemistry & Molecular Biology

Dorzagliatin in drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial

Dalong Zhu, Xiaoying Li, Jianhua Ma, Jiao'e Zeng, Shenglian Gan, Xiaolin Dong, Jing Yang, Xiaohong Lin, Hanqing Cai, Weihong Song, Xuefeng Li, Keqin Zhang, Qiu Zhang, Yibing Lu, Ruifang Bu, Huige Shao, Guixia Wang, Guoyue Yuan, Xingwu Ran, Lin Liao, Wenjuan Zhao, Ping Li, Li Sun, Lixin Shi, Zhaoshun Jiang, Yaoming Xue, Hongwei Jiang, Quanmin Li, Zongbao Li, Maoxiong Fu, Zerong Liang, Lian Guo, Ming Liu, Chun Xu, Wenhui Li, Xuefeng Yu, Guijun Qin, Zhou Yang, Benli Su, Longyi Zeng, Houfa Geng, Yongquan Shi, Yu Zhao, Yi Zhang, Wenying Yang, Li Chen

Summary: Dorzagliatin is a drug that improves insulin secretion and glycemic control in drug-naive patients with type 2 diabetes, showing good efficacy and safety.

NATURE MEDICINE (2022)

Article Biochemistry & Molecular Biology

Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial

Wenying Yang, Dalong Zhu, Shenglian Gan, Xiaolin Dong, Junping Su, Wenhui Li, Hongwei Jiang, Wenjuan Zhao, Minxiu Yao, Weihong Song, Yibing Lu, Xiuzhen Zhang, Huifang Li, Guixia Wang, Wei Qiu, Guoyue Yuan, Jianhua Ma, Wei Li, Ziling Li, Xiaoyue Wang, Jiao'e Zeng, Zhou Yang, Jingdong Liu, Yongqian Liang, Song Lu, Huili Zhang, Hui Liu, Ping Liu, Kuanlu Fan, Xiaozhen Jiang, Yufeng Li, Qing Su, Tao Ning, Huiwen Tan, Zhenmei An, Zhaoshun Jiang, Lijun Liu, Zunhai Zhou, Qiu Zhang, Xuefeng Li, Zhongyan Shan, Yaoming Xue, Hong Mao, Lixin Shi, Shandong Ye, Xiaomei Zhang, Jiao Sun, Ping Li, Tao Yang, Feng Li, Jingna Lin, Zhinong Zhang, Ying Zhao, Ruonan Li, Xiaohui Guo, Qi Yao, Weiping Lu, Shen Qu, Hongmei Li, Liling Tan, Wenbo Wang, Yongli Yao, Daoxiong Chen, Yulan Li, Jialin Gao, Wen Hu, Xiaoqiang Fei, Tianfeng Wu, Song Dong, Wenlong Jin, Chenzhong Li, Dong Zhao, Bo Feng, Yu Zhao, Yi Zhang, Xiaoying Li, Li Chen

Summary: In patients with inadequate glycemic control using metformin alone, dorzagliatin as an add-on therapy resulted in effective glycemic control with good tolerability and safety.

NATURE MEDICINE (2022)

Article Nutrition & Dietetics

Nutritional Status in Chinese Patients with Obesity Following Sleeve Gastrectomy/Roux-en-Y Gastric Bypass: A Retrospective Multicenter Cohort Study

Chunlan Zhang, Xi Chen, Shiping Liu, Wei Liu, Dalong Zhu, Xiaoying Li, Shen Qu, Zhiming Zhu, Jingjing Zhang, Zhiguang Zhou

Summary: Metabolic surgery has been shown to effectively treat obesity, but there is limited research on nutritional evaluations after surgery in Chinese patients. In this retrospective study, we found that Chinese patients undergoing metabolic surgery experienced changes in their nutritional status. Premenopausal females had a higher incidence of anemia at 12 months post-surgery, and preoperative anemia increased the risk of postoperative anemia. Ferritin levels decreased and iron deficiency increased among premenopausal females. However, there were no significant changes in folate deficiency and vitamin B12 deficiency throughout the study. Bone mineral density (BMD) significantly decreased from baseline to 12 months after surgery, but there were no new cases of osteopenia or osteoporosis. Nutrient supplements and long-term follow-up are necessary postoperation.

NUTRIENTS (2022)

Article Oncology

Ameliorative effects of miR-186 on cisplatin-triggered acute kidney injury via targeting ZEB1

Xiaoyan Xiong, Bo Tang, Tingting Ji, Xiaoying Li, Shoujun Bai

Summary: miR-186 levels are significantly decreased in AKI patients and cells exposed to cisplatin, and overexpression of miR-186 can enhance cell proliferation and protect against cisplatin-induced apoptosis. ZEB1 has been identified as a target gene of miR-186, and its inhibition rescues cell proliferation and apoptosis. Therefore, miR-186 may serve as an effective biomarker for AKI by targeting ZEB1.

AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH (2021)

暂无数据